|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||26.95 / 51.10|
The national program aims to reduce the volume of opioids prescribed following wisdom tooth extraction by 50 percent
Studies evaluate impact of EXPAREL administered as a regional nerve block for both upper and lower extremity surgeries
The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 1,627,603 share increase in total short interest for Pacira Pharmaceuticals Inc. , to 4,650,854, an increase of 53.84% since 07/31/2017.
Patients and their parents willing to pay more for an opioid alternative following wisdom tooth extraction to avoid side effects and risk of addiction
The most recent short interest data has been released for the 03/15/2017 settlement date, which shows a 1,240,223 share decrease in total short interest for Pacira Pharmaceuticals Inc. , to 5,113,726, a decrease of 19.52% since 02/28/2017.
Investors in Pacira Pharmaceuticals Inc. saw new options become available this week, for the November 17th expiration.
Collaboration will develop and standardize evidence-based, low-opioid strategies across Trinity Health's 22 states to benefit people and communities
Editas Medicine, Amphastar Pharmaceuticals, Aratana Therapeutics and Pacira Pharmaceuticals were among the biotech stock movers in premarket trading on Tuesday.
Pacira (PCRX) reported mixed fourth quarter results.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.